MX2020010618A - Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. - Google Patents

Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.

Info

Publication number
MX2020010618A
MX2020010618A MX2020010618A MX2020010618A MX2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
pyrazolotriazolopyrimidine
derivatives
pyrazolotriazolopyrimidine derivatives
stereoisomer
Prior art date
Application number
MX2020010618A
Other languages
English (en)
Spanish (es)
Inventor
Guoliang Zhang
Changyou Zhou
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2020010618A publication Critical patent/MX2020010618A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2020010618A 2018-04-08 2019-04-08 Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. MX2020010618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018082140 2018-04-08
PCT/CN2019/081785 WO2019196803A1 (en) 2018-04-08 2019-04-08 Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist

Publications (1)

Publication Number Publication Date
MX2020010618A true MX2020010618A (es) 2020-11-12

Family

ID=68163465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010618A MX2020010618A (es) 2018-04-08 2019-04-08 Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.

Country Status (15)

Country Link
US (1) US11472811B2 (https=)
EP (1) EP3774813A4 (https=)
JP (1) JP2021520392A (https=)
KR (1) KR20200140849A (https=)
CN (1) CN112313234B (https=)
AU (1) AU2019251148A1 (https=)
BR (1) BR112020020078A2 (https=)
CA (1) CA3095839A1 (https=)
EA (1) EA202092036A1 (https=)
IL (1) IL277744A (https=)
MX (1) MX2020010618A (https=)
SG (1) SG11202009706VA (https=)
TW (1) TW202010500A (https=)
WO (1) WO2019196803A1 (https=)
ZA (1) ZA202005772B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774813A4 (en) 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
KR20230049580A (ko) * 2020-03-26 2023-04-13 헵테얼즈 테라퓨틱스 리미티드 트리아졸론 화합물
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
WO2022087146A1 (en) 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
MXPA04003277A (es) 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
EP3774813A4 (en) 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
CN110742893B (zh) 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Also Published As

Publication number Publication date
SG11202009706VA (en) 2020-10-29
TW202010500A (zh) 2020-03-16
KR20200140849A (ko) 2020-12-16
US20210198267A1 (en) 2021-07-01
EA202092036A1 (ru) 2021-01-28
AU2019251148A1 (en) 2020-10-22
EP3774813A1 (en) 2021-02-17
US11472811B2 (en) 2022-10-18
CN112313234A (zh) 2021-02-02
WO2019196803A1 (en) 2019-10-17
BR112020020078A2 (pt) 2021-01-05
JP2021520392A (ja) 2021-08-19
CA3095839A1 (en) 2019-10-17
ZA202005772B (en) 2022-01-26
EP3774813A4 (en) 2021-11-17
CN112313234B (zh) 2022-04-29
IL277744A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
MX2023008954A (es) Inhibidores de los receptores erbb.
SG11201906579UA (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
PH12019501639A1 (en) Jaki selective inhibitors
TR201903322T4 (tr) Kinaz inhibisyonu için heteroaril bileşikleri.
MY202069A (en) Pharmaceutical composition
EA033689B9 (ru) Ингибиторы g12c kras
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2021007247A (es) Derivados de rapamicina.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
MX379576B (es) Derivados de azetidina
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof